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Abstract 
Background: Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public 
spaces. We previously identified 1,5‑anhydro‑d‑glucitol (1,5‑AG) in saliva as a diabetes biomarker. The Glycomark™ 
assay kit is FDA approved for 1,5‑AG measurement in blood. Here we evaluated its applicability for 1,5‑AG quantifica‑
tion in saliva.
Methods: Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona+ clinical chemistry 
analyser. We then used this set‑up to analyse 82 paired blood and saliva samples from a diabetes case–control study, 
for which broad mass spectrometry‑based characterization of the blood and saliva metabolome was also available. 
Osmolality was measured to account for potential variability in saliva samples.
Results: The technical variability of the read‑outs for the pooled saliva samples (CV = 2.05 %) was comparable to that 
obtained with manufacturer‑provided blood surrogate quality controls (CV = 1.38–1.8 %). We found a high correlation 
between Glycomark assay and mass spectrometry measurements of serum 1,5‑AG (r2 = 0.902), showing reproducibil‑
ity of the non‑targeted metabolomics results. The significant correlation between the osmolality measurements per‑
formed at two independent platforms with the time interval of 2 years (r2 = 0.887), also indicates the sample integrity. 
The assay read‑out for saliva was not correlated with the mass spectrometry‑based 1,5‑AG saliva measurements. 
Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read‑outs with galactose.
Conclusions: Glycomark™ assay read‑outs for saliva were stable and replicable. However, the signal was dominated 
by galactose, which is biochemically similar to 1,5‑AG and absent in blood. Adapting the 1,5‑AG kit for saliva analysis 
will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for 
glucose depletion from blood samples.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Diabetes incidence has dramatically increased in recent 
years [1], with estimates suggesting that diabetes will 
affect 7.7  % of all adults (439 million) worldwide by 
2030 [2]. This epidemic is particularly impacting coun-
tries in the Gulf region—including Qatar, the United 
Arabic Emirates, and Saudi Arabia—where diabetes 
affects around 20 % of the adult population, and there is 
a relatively high rate of undiagnosed diabetes, including 
among young adults and children [3, 4]. Uncontrolled 
diabetes, manifested by periods of hypo- or hyper-gly-
caemia, can lead to the development of chronic comor-
bidities of diabetes, including cardiovascular disease, 
retinopathies, and nephropathies [5]. Early diagnosis 
enables tight glycaemic control, and can improve patient 
outcomes by delaying or avoiding chronic complications. 
Most diabetes-related medical costs are associated with 
chronic complications and comorbidities [6]. Therefore, 
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levels within the targeted range are fundamental for both 
patients and their health systems.
The blood level of haemoglobin A1c (HbA1C) is a 
clinically well-established marker of long-term glycae-
mic control [7]. The haemoglobin glycosylation rate 
depends on the blood glucose concentration, and there-
fore reflects long-term glycaemic control associated 
with erythrocyte turnover [8]. The American Diabetes 
Association recommends HbA1C monitoring as a stand-
ard protocol for patients with diabetes, along with self-
monitoring of blood glucose levels [9]. A commonly used 
marker of short-term glycaemic control is 1,5-anhydro-
D-glucitol (1,5-AG), a metabolically stable small mol-
ecule (metabolite) that is well absorbed in the intestinal 
tract and mainly originates from the diet [10]. In healthy 
individuals, 1,5-AG blood level remains relatively con-
stant due to equilibrium between 1,5-AG absorption, 
urinary reabsorption, and secretion by the intestinal tract 
[10], with little or no biochemical transformation in the 
body. In hyperglycaemia (above the renal threshold of 
180 mg/mL), this equilibrium is upset by increased 1,5-
AG secretion caused by competitive inhibition of urinary 
reabsorption by glucose. Based on this process, biochem-
ical assays have been developed to monitor 1,5-AG as a 
marker of short-term glycaemic control [11].
Monitoring blood 1,5-AG levels to assess short-term 
glycaemic control was introduced into clinical practice 
in Japan over 20 years ago [12, 13], and was established 
worldwide in 1996 [14]. Today, automated and quan-
titative 1,5-AG measurement can be performed using 
the commercially available biochemical assay kits Gly-
comarkTM (GlycoMark, Inc., USA) [15, 16], and Deter-
miner-L (Kyowa Medex, Japan) [11]. In 2003, the US 
FDA approved the use of the GlycomarkTM assay for 
monitoring 1,5-AG as a marker of short-term blood glu-
cose levels [17], which has since been evaluated in sev-
eral clinical studies [18–22]. The first US clinical trial of 
the GlycomarkTM assay demonstrated that 1,5-AG levels 
sensitively and rapidly reflected glycaemia changes fol-
lowing personalized treatment strategy modifications—
including changes in medication types or dosage, and 
initiation of insulin therapy or combination of different 
insulin regimens [22]. Another clinical trial used 1,5-AG 
measurements to compare two distinct insulin regimens 
in 233 patients with T2D, showing that 1,5-AG levels 
significantly differentiated between patients receiving 
different treatments, consistent with the independently 
monitored glucose profiles [18]. The authors of that study 
suggested 1,5-AG level monitoring as a tool for selecting 
and optimizing therapy for T2D patients [18].
We recently employed mass spectrometry (MS) com-
bined with non-targeted metabolomics to identify type 
2 diabetes (T2D)-associated metabolites in saliva, blood, 
and plasma samples [23, 24]. In a cross-sectional case/
control study including 188 cases and 181 controls, we 
searched for diabetes biomarkers in saliva or urine sam-
ples that could enable development of a non-invasive 
strategy for diabetes screening and monitoring. We 
found that 1,5-AG levels in both saliva and plasma sam-
ples significantly distinguished diabetic patients from 
healthy controls. Moreover, 1,5-AG levels in plasma were 
significantly correlated with 1,5-AG levels in blood [23]. 
Our results support the possibility of measuring saliva 
1,5-AG level as a new non-invasive strategy to be used 
together with HbA1C for diabetes screening and assess-
ment of glycaemic control.
Although our previous findings indicate that all clini-
cally established properties of the 1,5-AG blood marker 
can be extrapolated to its saliva equivalent, there is pres-
ently no easy and scalable method for 1,5-AG measure-
ment in saliva in a clinical setting. Given the established 
value of 1,5-AG monitoring in diabetes care, and the 
availability of a biochemical assay to measure 1,5-AG in 
blood, here we aimed to evaluate the applicability of the 
Glycomark™ assay for monitoring 1,5-AG in saliva.
We tested assay robustness and reproducibility by 
repetitive measurements of identical saliva samples in a 
single machine run as well as over a period of 5 days in 
replicates. For validation purposes, we measured with 
Glycomark™ assay 82 paired plasma and saliva samples, 
for which broad mass spectrometry-based characteriza-
tion metabolome was also available together with osmo-
lality measurements for saliva. The correlation between 
assay readouts and metabolite intensities was determined 
to rule out potential sample mix-up.
Methods
Study design
This study was a collaboration between the Translational 
Research Institute (TRI) of Hamad Medical Corpora-
tion (HMC) and Weill Cornell Medical College-Qatar 
(WCMC-Q). The study design included two phases. 
First, we evaluated the stability and reproducibility of 
1,5-AG measurements using the Glycomark™ assay 
using kit-provided control samples (surrogate serum 
matrix spiked with 1,5-AG) and pooled saliva samples 
from healthy individuals. Second, we used the Glyco-
mark™ assay to analyse 82 paired saliva and plasma sam-
ples that were previously analysed using a non-targeted 
metabolomics platform [23]. The 1,5-AG measurements 
were performed 2 years after initial metabolomics study. 
Independent measurement of this parameter was per-
formed to account for the potential variability in saliva 
osmolality.
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Preparation of a saliva master mix
Saliva samples were collected from 24 healthy individu-
als using the Salivette® system, following the manufac-
turer’s recommendations. Briefly, each donor was first 
asked to rinse their mouth with water. They were then 
asked to chew the Salivette roll for 1 min so that it could 
absorb their saliva. The chewed Salivette roll was placed 
into the Salivette® tube, which was centrifuged at 2500g 
for 10 min at 4 °C. After centrifugation, 200 µL of saliva 
was transferred into a collection tube. To create a pooled 
sample, we also transferred 850 µL from each tube into a 
50 mL collection tube. The saliva mix was vortexed and 
transferred in aliquots of 200 µL to 102 vials, which were 
frozen at −80 °C until analysis. In the following sections, 
these samples are referred to as master mix (MM). The 
individual samples in separate collection tubes were also 
frozen at −80 °C until analysis.
Characteristics of individual samples evaluated 
by non‑targeted metabolomics and biochemical assay
We used blood and saliva samples collected as part of the 
Qatar Metabolomics Study on Diabetes (QMDiab) study 
protocol, which was approved by the Institutional Review 
Boards of HMC and Weill Cornell Medical College-Qatar 
(WCMC-Q) (research protocol number 11131/11). All 
study participants gave their written informed consent 
and authorized utilization of their samples for future 
research. The samples were de-identified, and a cer-
tificate of non-human research was obtained from the 
WCMC-Q research compliance office.
The QMDiab study was a collaboration between the 
Dermatology Department of Hamad Medical Corpora-
tion (HMC) and Weill Cornell Medical College-Qatar 
(WCMC-Q), and has been previously described [23, 24]. 
The primary aim was to identify metabolic markers of 
diabetes in saliva, blood, and urine samples. Briefly, ques-
tionnaires were used to collect information regarding age, 
gender, ethnicity, and history of T2D. Non-fasting saliva, 
plasma, and urine samples were collected and processed 
following standardized protocols [23]. HbA1C levels 
were measured at the Department of Laboratory Medi-
cine and Pathology of HMC (Cobas 6000; Roche Diag-
nostics). Metabolic profiling of plasma, saliva, and urine 
samples was performed using a non-targeted metabo-
lomics platform (Metabolon). A total of 2178 metabolites 
were analysed in 1043 samples [23].
For our present study, we retrieved 82 de-identified 
samples: 49 from healthy controls and 28 from patients 
with diabetes, selected based on the information regard-
ing the history of T2D from questionnaires. This sample 
subset was selected based on the availability of surplus 
saliva aliquots. Table  1 presents the HbA1C values and 
age and gender data for this study group.
Metabolomics measurements
Metabolite profiling was performed at Metabolon Inc., 
using ultra-high-performance liquid chromatography-
mass spectrometry (UPLC-MS) and gas chromatography-
mass spectrometry (GC–MS) as previously described [25]. 
Briefly, saliva and plasma samples were extracted using a 
series of organic and aqueous solvents to remove the pro-
tein fraction. To analyse samples using both the UPLC-
MS and GC–MS approaches, each extracted sample was 
divided into two equal parts. The organic solvent was 
removed and the samples were frozen and vacuum-dried.
The samples for UPLC-MS analysis were reconstituted 
in an acidic or basic solution compatible with LC-sol-
vents. Extracts reconstituted in acidic conditions were 
measurements in acidic positive ion, optimized condi-
tions and extracts reconstituted in basic conditions were 
measured in basic negative ion, optimized conditions. 
Measurements were performed on Waters ACQUITY 
UPLC system and a Thermo-Finnigan LTQ mass spec-
trometer equipped with an electrospray ionization (ESI) 
source and a linear ion-trap (LIT) mass analyser [25].
The GC–MS samples were derivatised prior to analysis. 
Sample separation was performed on a 5 % diphenyl/95 % 
dimethyl polysiloxane GC column, with helium as the 
carrier gas, and the temperature ramping up from 60° 
to 340 °C over 17.5 min. Measurements were performed 
on a Thermo-Finnigan Trace DSQ fast-scanning single-
quadruple mass spectrometer using electron impact ioni-
zation [24].
Peaks were identified using Metabolon’s propriety peak 
integration software, which compared the obtained data 
to library entries for purified standards or unknown 
recurrent entities. For each sample, library matches for 
each compound were checked, and manually corrected 
if necessary. Metabolite levels were scaled in accordance 
with run-day medians.
Osmolality measurements
Osmolality measurements were performed on samples 
submitted for metabolomics analysis in 2013 by Metab-
olon Inc., and on samples used with the biochemistry 
Table 1 Sample characteristics
Age and HbA1C values are shown as median (range); female sex is shown as 
number of subjects (percentage)
a All subjects, including 49 control subjects, 28 patients with type 2 diabetes, 
and 5 subjects for whom no information was available regarding health 
condition
Subject Control  
(n = 49)
Type 2 diabetes 
(n = 28)
All (n = 82)a
Age, years 46.7 (26–71) 42.4 (24–67) 47.2 (24–71)
Female sex 26 (53 %) 15 (54 %) 44 (54 %)
HbA1C, µg/mL 6.3 (4.7–9.4) 6.5 (4.7–12.4) 6.5 (4.7–12.4)
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assay in 2015 by iTRI. Both sets of measurements were 
performed using a freezing-point Fiske Micro-Osmome-
ter Model 210. Osmolality was determined using 20 µL of 
sample, and measurements were performed in duplicate. 
The osmometer was calibrated daily using standards for 
saliva (50 mmol/kg) [26].
Biochemical assay to measure 1,5‑AG
We attempted to quantify 1,5-AG in the saliva and 
plasma samples using the commercially available Gly-
coMark™ kit (Tomen America, New York, NY), follow-
ing the manufacturer’s recommendations as previously 
described [16].
The assay consists of two main steps. In the first step, 
glucose is eliminated from the sample. In the second 
step, pyranose oxidase (PROD) kinetic efficiency of C-2 
hydroxyl group oxidation of 1,5-AG is measured by 
hydrogen peroxide formation, which is detected by col-
orimetry using peroxidase (POD). This reaction can be 
monitored at 546  nm (primary wavelength). To correct 
for background or nonspecific reading the absorbance at 
700 nm is also measured. Glucose is eliminated from the 
sample because it can serve as a substrate for PROD.
The kit components allow execution of these steps in a 
clinical chemistry analyser. Briefly, all reactions were per-
formed at 37  °C in the RX daytona+ clinical chemistry 
analyser (Randox Laboratories, Ltd.) programmed accord-
ing to the manufacturer’s protocol. The kit includes two 
different reagents (Reagent 1 and Reagent 2) that are opti-
mized for two sequential steps performed in a fully auto-
mated way. First, 4 µL of sample was mixed with 120 µL 
of Reagent 1 and incubated for 5 min. Reagent 1 contains 
glucokinase to eliminate glucose from the sample. Next, 
60 µL of Reagent 2, containing PROD was added, and the 
reaction kinetic was monitored by measuring absorbance 
immediately, and after 10 min at 546 nm (primary wave-
length) and 700 nm (secondary wavelength).
The 1,5-AG concentration in the sample is automati-
cally calculated as follows: (1) The absorbance values 
determined at 700 nm were subtracted from those deter-
mined at 546 nm; (2) The kinetic difference in absorbance 
between the second and first measurements was calcu-
lated; (3) The 1,5-AG concentration in the sample was 
determined by comparison with the kinetic changes in 
the absorbance of the reagent blank and of the standard 
provided in the kit.
To ensure reproducibility, the instrument was cali-
brated daily with a calibration standard provided by Gly-
coMark™. To verify measurement precision, we included 
two levels of controls prepared in surrogate serum matrix 
with 1,5-AG concentrations of ~4.0–5.5 µg/mL (low-level 
control) and ~13.0–16.0 µg/mL (high-level control), both 
provided by GlycoMark™.
Statistical data analysis
All statistical analyses were performed using R version 
3.1.3 and R-Studio version 0.97.551. The package ‘stats’ 
version 3.1.3 was used to calculate linear regression. For 
each identified metabolite the raw area ion counts were 
normalized to the median value of the run day and the 
data were z-scored before computing the statistics. Lin-
ear regression was applied to assess the statistical sig-
nificance of the association between the metabolite 
intensities determined using non-targeted metabolomics 
approaches and the 1,5-AG concentrations determined 
by biochemical assay. The statistical significance of the 
correlation between the results of non-targeted metabo-
lomics and the 1,5-AG measurements performed via 
biochemical assay was inferred with the use of stringent 
Bonferroni correction to account for testing 1360 metab-
olites (p < 0.05/1360 = 3.67 × 10−5).
Results
Correlation between mass spectrometry and biochemical 
assay measurements of 1,5‑AG in blood
We first tested the compatibility of the Glycomark 
assay with the RX daytona+ clinical chemistry analyser 
(Randox Laboratories, Ltd.), as this equipment was not 
explicitly specified by the manufacturer. To verify that 
the assay functioned correctly on this instrument, we 
determined the measurement variability of the high-
level (~4.0–5.5  µg/mL 1,5-AG) and low-level (~13.0–
16.0  µg/mL 1,5-AG) quality controls. Over a period 
of 5  days, we measured a total of 42 low-level and 42 
high-level quality control samples. The average meas-
ured concentrations were 4.94 and 14.57 µg/mL, respec-
tively. Day-to-day variability in the measurements was 
minimal for both low-level (CV = 1.8 %) and high-level 
(CV  =  1.38  %) quality control samples. Our measure-
ments were comparable to previous measurements 
performed using the Glycomark-certified Hitachi 917 
analyser (low-level control, 4.7  µg/mL, CV  =  3.71  %; 
and high-level control, 14.7 µg/mL, CV = 1.35 % [16]), 
thus demonstrating that the Glycomark assay is also 
compatible with the presently used RX daytona+ clinical 
chemistry analyser.
Next, we tested whether the 1,5-AG concentrations 
determined with the Glycomark assay correlated with 
the semi-quantitative 1,5-AG levels measured in plasma 
using non-targeted metabolomics (expressed in run-day 
normalized ion-counts). We found a highly significant 
correlation between both measurements in plasma sam-
ples, as shown in Fig.  1a (p =  2.6 ×  10−42, r2 =  0.902). 
This finding demonstrated the reproducibility of non-tar-
geted metabolomics results using the biochemical assay, 
simultaneously confirming the high quality of both ana-
lytical methods.
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We also examined whether the assay read-outs 
from the plasma samples correlated with any other 
metabolite measured using the non-targeted metabo-
lomics platform. We found two unknown metabolites 
X-19437 (p value =  4.85×10−6, r2 =  0.22) and X-18221 
(p-value = 1.25×10−4, r2 = 0.16), which showed signifi-
cant correlation with assay readouts.
Low variability of the Glycomark assay for saliva
Novatzke et al. [16] previously evaluated the variability of 
the Glycomark assay by assaying two replicates of pooled 
serum samples, twice a day, over a period of 10 days. The 
between-assay variability of pooled serum samples was 
very low (CV = 1.17 %) and comparable with quality con-
trols. Here we evaluated the variability of the Glycomark 
assay by measuring 20 samples of pooled saliva in a sin-
gle assay run (within-assay variability), and by measur-
ing 59 samples in at least triplicate over a 5-day period 
(between-assay variability) (Table 2A). We found very low 
variability in the saliva measurements in a single assay 
run (1.7 %), and between different assay runs performed 
on different days (2.05  %). These values are comparable 
to the variability of the quality control measurements 
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Fig. 1 a Correlation between 1,5‑AG intensities determined using the non‑targeted semi‑quantitative mass spectrometry (MS)‑based metabo‑
lomics platform and the 1,5‑AG concentrations measured with the quantitative Glycomark biochemical assay in two plasma aliquots from the same 
patient. b Correlation between osmolality measurements of saliva performed using identical instruments but on two individual platforms (TRI and 
Metabolon) with a time interval of 2 years. c Correlation between 1,5‑AG intensities determined using the non‑targeted MS‑based metabolomics 
platform and the 1,5‑AG concentrations determined with Glycomark assay in saliva. d Scatterplot of Glycomark assay read‑outs from saliva and 
galactose intensities determined using the non‑targeted MS‑based metabolomics platform
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samples [16]. Our results suggest that saliva is a stable 
matrix for application of the Glycomark™ assay.
Osmolality of saliva samples analysed on two independent 
platforms
We first evaluated the technical variability of osmolality 
measurements on our TRI platform using pooled saliva 
samples prior to the 1,5-AG measurements. Table  2B 
shows the low variation among measurements performed 
on the same day (CV = 1.3 %) and over the 5-day period 
(CV  =  1.4  %). We next compared osmolality measure-
ments performed using aliquots of the same saliva sam-
ples, but run at two sites (Metabolon and TRI) using 
same equipment. For this comparison, we determined 
the osmolality of 82 saliva samples for which the osmo-
lality was previously measured at Metabolon. We found 
that the two data sets were highly correlated, as shown 
in Fig. 1b (p = 8.52 × 10−40, r2 = 0.887). These findings 
confirm the quality of the osmolality measurements and, 
in particular, exclude the possibility of accidental sample 
interchange.
Glycomark assay read‑out in saliva correlates 
with galactose intensity
Using the Glycomark assay, we analysed 82 saliva sam-
ples. As shown in Fig.  1c, we found a very low correla-
tion between 1,5-AG intensities and assay read-outs 
(p  =  0.028, r2  =  0.047). Thus, we further examined 
whether the assay read-outs from the saliva samples 
correlated with any other metabolite measured using 
the non-targeted metabolomics platform. Table  3 pre-
sents the 12 metabolites that we identified as being 
significantly correlated with the Glycomark assay read-
out, which included 6 carbohydrates, 2 amino acids, 
1 lipid, 1 peptide, and 2 unknown metabolites. By far, 
the strongest correlation was observed with galactose 
(p = 4.68 × 10−23, r2 = 0.704) (Fig. 1d). We next identi-
fied all correlations between galactose and other metab-
olites determined using non-targeted metabolomics in 
saliva. This analysis revealed 42 metabolites that signifi-
cantly correlated with galactose, among which 10 were 
also significantly correlated with the Glycomark assay 
read-outs from saliva (Table 3).
Discussion
In our present study, we evaluated a possible method for 
measuring 1,5-AG in saliva samples using a set-up com-
patible with clinical analytical laboratories. The 1,5-AG 
could be quantified in saliva samples using NMR as well 
as LC/MS based targeted metabolomics approach, how-
ever it implementation into the clinical setting is limited 
[27]. Thus, we deployed an automated biochemical assay 
for 1,5-AG concentrations (Glycomark kit) to analyse 
plasma and saliva samples for which metabolic profiles 
had previously been determined [23]. Our results showed 
a highly significant correlation between the plasma 1,5-
AG levels determined by non-targeted metabolomics and 
those measured with the Glycomark assay, demonstrat-
ing a good agreement between the two methods. How-
ever, we found no corresponding correlation of apparent 
1,5-AG levels in saliva samples.
Previous studies investigated and ruled out cross-reac-
tivates of assay readouts in blood [15]. We confirmed that 
the dominant signal is from 1,5-AG (p-value = 2.6×10−42 
and r2 = 0.902). Two metabolites of unknown id, presum-
ably carbohydrates [24], show some correlation but the 
signal was much weaker than the 1,5-AG signal. How-
ever, the cross-reactivity in saliva samples was not tested 
Table 2 Assay variability in saliva samples. (A) Variability in 1,5-AG measurements with GlycoMark assay. (B) Variability 
in osmolality measurements with FISKO osmometer
a Table shows that the GlycoMark assays yield reliable and reproductive measurements in saliva. The coefficient of variation (CV) is expressed in percentage and the 
assay read-out in µg/mL
b Table shows that the osmolality measurements have a very low variability. The coefficient of variation (CV) is expressed in percentage and the osmolality in 
mOsmol/kg
Within‑assay variability Between‑assay variability
Master mix Master mix Control low Control high
(A) GlycoMark assaya
 Number of samples 20 59 42 42
 Average 1,5‑AG, µg/mL 4.08 4.11 4.94 14.6
 CV,  % 1.70 2.05 1.80 1.38
(B) Osmolality measurementsb
 Number of samples 20 59 – – 
 Average osmolality, mOsmol/kg 59 59 – – 
 CV, % 1.31 1.40 – – 
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before, and the lack of correlation in saliva could be due 
to the assay interference.
We detected a correlation between parallel osmolal-
ity measurements, excluding the possibility of potential 
sample switching. Further investigation revealed a high 
correlation between the kit read-out and the galactose 
intensities in saliva samples, suggesting that galactose 
might have interfered with the assay measurements. 
In the non-targeted metabolomics data, we found that 
the 1,5-AG read-outs of the biochemistry assay corre-
lated with the following 12 saliva metabolites: galactose, 
N-acetylglucosamine, fucose, xylose, mannose, O-acetyl-
serine, putrescine, ribose, 1,2-propanediol, lysylproline, 
and the unknown metabolites X-14904 and X-18059 
(see Table  3), with the strongest correlation observed 
for galactose. Therefore, we hypothesize that galactose 
was the dominant molecule interfering with our 1,5-AG 
measurements.
This phenomenon could conceivably be associated with 
nonspecific activity of the enzyme involved in the final 
step of the Glycomark assay. In the sequential reactions, 
pyranose oxidase (PROD) catalyses oxidation of the C-2 
hydroxyl group of 1,5-AG. However, PROD can also 
catalyse oxidation of several other carbohydrates at the 
2-OH moiety of the pyranose ring structure [28]. Since 
glucose serves as a PROD substrate, the assay includes 
an initial step to enzymatically modify glucose and thus 
minimize interference [16]. In plasma, only glucose is 
present at a level that could potentially interfere with 
assay read-outs, with other monosaccharides detected at 
only very low levels [28]. We found that saliva also con-
tains glucose, along with galactose, fucose, xylose, and 
mannose, which could each potentially serve as a PROD 
substrate and hence interfere with the assay read-outs. A 
previous study examined PROD affinity towards several 
sugar alcohols relative to 1,5-AG, and reported the fol-
lowing affinity ranking: xylose>glucose>galactose>sorb
ose>glucano-lactone>mannose [28]. Another study also 
showed that fucose is a PROD substrate [29]. Although 
we detected xylose and mannose in plasma samples, 
the concentrations were insufficient to interfere with 
the measurements, since we observed a significant cor-
relation between 1,5-AG measured with non-targeted 
metabolomics and the Glycomark assay. In contrast, we 
detected glucose and several other monosaccharides in 
saliva. The lack of correlation between glucose and assay 
read-outs in saliva demonstrated that saliva provides a 
stable environment for glucokinase activity, which cataly-
ses glucose modification.
Further analysis revealed that almost all metabolites 
(except the unknown metabolites X-14904 and X-18059) 
that significantly correlated with assay read-outs, also 
significantly correlated with galactose, regardless of 
their chemical structure. Furthermore, the correlations 
between metabolites and galactose concentrations were 
more strongly significant than the correlations between 
metabolites and the assay read-outs. Thus, we hypoth-
esises that galactose is a major interference of the 1,5-AG 
measurements, and fucose, xylose, and mannose show 
significant correlations with the assay read-outs because 
Table 3 Metabolites significantly correlating with  assay read-out overlap with  metabolites significantly correlating 
with galactose
The association trend was positive for all significantly correlating metabolites. We analysed correlation of those metabolites with galactose, which correlation with 
assay read-out was the strongest. No significance in correlation between metabolites and galactose is expressed as NS. We applied linear regression (lm) of 1,5-AG 
measured with Glycomark (AG_Sal_H) against 1,5-AG measured on non-targeted metabolomics platform (AG_Sal_M) and corrected on the covariate (met), listed in 
the “Metabolite name” column. Metabolites with similar chemical structure to 1,5-AG are highlighted in italics






r2 p r2 p p
Galactose Carbohydrate 0.704 4.7 × 10−23 – – –
N‑acetylglucosamine Carbohydrate 0.436 9.2 × 10−12 0.787 7.8 × 10−29 2.5 × 10−03
Fucose Carbohydrate 0.376 5.4 × 10−10 0.542 3.1 × 10−15 0.99
Xylose Carbohydrate 0.318 2.5 × 10−08 0.506 6.1 × 10−14 0.47
Mannose Carbohydrate 0.276 2.3 × 10−07 0.396 1.4 × 10−10 0.97
O‑acetylserine Amino acid 0.355 1.9 × 10−06 0.524 7.9 × 10−10 0.84
Putrescine Amine 0.234 2.5 × 10−06 0.451 3.0 × 10−12 0.09
Ribose Carbohydrate 0.232 2.7 × 10−06 0.403 9.0 × 10−11 0.31
1,2‑propanediol Lipid 0.200 1.5 × 10−05 0.279 2.0 × 10−07 0.89
X‑14904 Unknown 0.186 3.0 × 10−05 NS NS 2.2 × 10−04
X‑18059 Unknown 0.186 3.1 × 10−05 NS NS 5.9 × 10−04
Lysylproline Peptide 0.185 3.3 × 10−05 0.413 4.5 × 10−11 0.02
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they correlate with galactose rather than because they 
interfere with the measurements.
To investigate whether galactose was the main metabo-
lite interfering with our measurement, we analysed the 
data using a linear model including galactose as a covari-
ate. In this model, we tested the contribution of each 
metabolite that was found to significantly correlate with 
assay read-outs: (lm(AG_Sal_H~metabolite  +  galac-
tose)). As shown in Table  3, none of the other metabo-
lites contributed significantly. Hence, our data was totally 
dominated by the galactose signal. Furthermore, any 
potential contribution from 1,5-AG or other signals was 
lost in the background measurement noise. The galactose 
signal cannot be mathematically corrected and requires 
evaluation in the laboratory setting.
Conclusions
With this study we showed feasibility and limitations 
of monitoring of 1,5-AG using Glycomark™ assay in 
saliva, as method to facilitate diabetes screening. The 
replicable assay readouts from saliva samples showed 
that saliva serve as stable matrix for biochemical assay. 
However, the signal was dominated by galactose, which 
is biochemically similar to 1,5-AG and absent in blood. 
In future experiments, we will attempt to improve the 
assay by introducing an enzymatic step to remove galac-
tose before sample processing, which should increase the 
assay specificity for salivary 1,5-AG. Further optimization 
of the assay for 1,5-AG measurement in saliva will likely 
result in a versatile tool for diabetes screening and moni-
toring that will improve T2D diagnosis, especially in pae-
diatric patients, and this is one of our future study goals.
Authors’ contributions
This manuscript has been read and approved by all the authors, the require‑
ments for authorship have been met and each author believes that the manu‑
script represents honest work. Study design: AH, KS, MK, ABAS, RMM. Sample 
processing and measurements: AH, MK, NJS, SAK. Statistical data analysis: AH, 
KS. Manuscript writing: AH, MK, KS. Critical revision of the manuscript: RMM, 
ABAS, KS, MK. All authors read and approved the final manuscript.
Author details
1 Department of Physiology and Biophysics, Weill Cornell Medicine‑Qatar, 
Qatar‑Foundation, P.O Box: 24144, Doha, Qatar. 2 Translational Research 
Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, 
Doha, Qatar. 3 Department of Internal Medicine, Hamad Medical Corporation, 
Doha, Qatar. 4 Institute of Bioinformatics and Systems Biology, Helmholtz 
Zentrum München, German Research Center for Environmental Health, 
Neuherberg, Germany. 
Acknowledgements
This work was supported by Biomedical Research Program funds at Weill 
Cornell Medical College in Qatar, a program funded by the Qatar Foundation. 
The authors are solely responsible for the statements made herein.
Competing interests
The authors declare that they have no competing interests.
Original Publication
Manuscript contains original unpublished work and is not being submitted for 
publication elsewhere at the same time.
Received: 21 January 2016   Accepted: 5 May 2016
References
 1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. 
National, regional, and global trends in fasting plasma glucose and 
diabetes prevalence since 1980: systematic analysis of health exami‑
nation surveys and epidemiological studies with 370 country‑years 
and 2·7 million participants. Lancet. 2011;378:31–40. doi:10.1016/
S0140‑6736(11)60679‑X.
 2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of dia‑
betes for 2010 and 2030. Diab Res Clin Pract. 2010;87:4–14. doi:10.1016/j.
diabres.2009.10.007.
 3. Alharbi NS, Almutari R, Jones S, Al‑Daghri N, Khunti K, de Lusignan S. 
Trends in the prevalence of type 2 diabetes mellitus and obesity in the 
Arabian Gulf States: systematic review and meta‑analysis. Diab Res Clin 
Pract. 2014;106:e30–3. doi:10.1016/j.diabres.2014.08.019.
 4. Klautzer L, Becker J, Mattke S. The curse of wealth—Middle Eastern 
countries need to address the rapidly rising burden of diabetes. Int J Heal 
Policy Manag. 2014;2:109–14. doi:10.15171/ijhpm.2014.33.
 5. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol 
Rev. 2013;93:137–88. doi:10.1152/physrev.00045.2011.
 6. Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, et al. Medical 
costs associated with type 2 diabetes complications and comorbidities. 
Am J Manag Care. 2013;19:421–30. http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=4337403&tool=pmcentrez&rendertype=abstr
act Accessed 9 June 2015.
 7. Bunn HF, Haney DN, Gabbay KH, Gallop PM. Further identification of the 
nature and linkage of the carbohydrate in hemoglobin A1c. Biochem 
Biophys Res Commun. 1975;67:103–9. http://www.ncbi.nlm.nih.gov/
pubmed/1201013 Accessed 9 June 2015.
 8. Dagogo‑Jack S. Pitfalls in the use of HbA1(c) as a diagnostic test: the 
ethnic conundrum. Nat Rev Endocrinol. 2010;6:589–93. doi:10.1038/
nrendo.2010.126.
 9. American Diabetes Association. Executive summary: standards of medical 
care in diabetes–2012. Diab Care. 2012;35(Suppl 1):S4–10. doi:10.2337/
dc12‑s004.
 10. Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromi‑
zato H, et al. Origin and disposal of 1,5‑anhydroglucitol, a major polyol in 
the human body. Am J Physiol. 1992;263:E268–73. http://www.ncbi.nlm.
nih.gov/pubmed/1514606 Accessed 9 June 2015.
 11. Selvin E, Rynders GP, Steffes MW. Comparison of two assays for serum 
1,5‑anhydroglucitol. Clin Chim Acta. 2011;412:793–5. doi:10.1016/j.
cca.2011.01.007.
 12. Yamanouchi T, Akanuma Y. Serum 1,5‑anhydroglucitol (1,5 AG): 
new clinical marker for glycemic control. Diab Res Clin Pract. 
1994;24(Suppl):S261–8. http://www.ncbi.nlm.nih.gov/pubmed/7859616 
Accessed 26 Sep 2015).
 13. Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, et al. 
Comparison of 1,5‑anhydroglucitol, HbA1c, and fructosamine for detec‑
tion of diabetes mellitus. Diabetes. 1991;40:52–7. http://www.ncbi.nlm.
nih.gov/pubmed/2015974 Accessed 29 July 2015.
 14. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. 
Clinical usefulness of serum 1,5‑anhydroglucitol in monitoring glycaemic 
control. Lancet (London, England). 1996;347:1514–8. http://www.ncbi.
nlm.nih.gov/pubmed/8684103 Accessed 26 Sep 2015.
 15. Fukumura Y, Tajima S, Oshitani S, Ushijima Y, Kobayashi I, Hara F, et al. Fully 
enzymatic method for determining 1,5‑anhydro‑D‑glucitol in serum. Clin 
Chem. 1994;40:2013–6. http://www.ncbi.nlm.nih.gov/pubmed/7955370 
Accessed 20 Sep 2015.
Page 9 of 9Halama et al. J Transl Med  (2016) 14:140 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 16. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation 
of an assay for serum 1,5‑anhydroglucitol (GlycoMark) and determina‑
tion of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta. 
2004;350:201–9. doi:10.1016/j.cccn.2004.08.013.
 17. Dungan KM. 1,5‑anhydroglucitol (GlycoMark) as a marker of short‑
term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 
2008;8:9–19. doi:10.1586/14737159.8.1.9.
 18. Moses AC, Raskin P, Khutoryansky N. Does serum 1,5‑anhydroglucitol 
establish a relationship between improvements in HbA1c and postpran‑
dial glucose excursions? supportive evidence utilizing the differential 
effects between biphasic insulin aspart 30 and insulin glargine. Diab Med. 
2008;25:200–5. doi:10.1111/j.1464‑5491.2008.02384.x.
 19. Skupien J, Gorczynska‑Kosiorz S, Klupa T, Wanic K, Button EA, Sieradzki J, 
et al. Clinical application of 1,5‑anhydroglucitol measurements in patients 
with hepatocyte nuclear factor‑1 maturity‑onset diabetes of the young. 
Diab Care. 2008;31:1496–501. doi:10.2337/dc07‑2334.
 20. Peixoto EML, Bozkurt NC, Messinger S, García MIDO, Lauriola V, Corrales 
A, et al. The use of 1.5‑anhydroglucitol for monitoring glycemic control in 
islet transplant recipients. Cell Transpl. 2014;23:1213–9. doi:10.3727/09636
8913X669734.
 21. Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, et al. The inter‑
relationships of glycemic control measures: HbA1c, glycated albumin, 
fructosamine, 1,5‑anhydroglucitrol, and continuous glucose monitoring. 
Pediatr Diab. 2011;12:690–5. doi:10.1111/j.1399‑5448.2011.00764.x.
 22. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, et al. 
Circulating 1,5‑anhydroglucitol levels in adult patients with diabetes 
reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark 
assay. Diab Care. 2004;27:1859–65. http://www.ncbi.nlm.nih.gov/pub‑
med/15277408 Accessed 20 Sep 2015.
 23. Mook‑Kanamori DO, Selim MME‑D, Takiddin AH, Al‑Homsi H, Al‑
Mahmoud KAS, Al‑Obaidli A, et al. 1,5‑Anhydroglucitol in saliva is a non‑
invasive marker of short‑term glycemic control. J Clin Endocrinol Metab. 
2014;99:E479–83. doi:10.1210/jc.2013‑3596.
 24. Yousri NA, Mook‑Kanamori DO, Selim MME‑D, Takiddin AH, Al‑Homsi H, 
Al‑Mahmoud KAS, et al. A systems view of type 2 diabetes‑associated 
metabolic perturbations in saliva, blood and urine at different timescales of 
glycaemic control. Diabetologia. 2015;. doi:10.1007/s00125‑015‑3636‑2.
 25. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, 
nontargeted ultrahigh performance liquid chromatography/electrospray 
ionization tandem mass spectrometry platform for the identification and 
relative quantification of the small‑molecule complement of biological 
systems. Anal Chem. 2009;81:6656–67. doi:10.1021/ac901536h.
 26. Cheuvront SN, Ely BR, Kenefick RW, Sawka MN. Biological variation and 
diagnostic accuracy of dehydration assessment markers. Am J Clin Nutr. 
2010;92:565–73. doi:10.3945/ajcn.2010.29490.
 27. Li S, Heng X, Sheng H, Wang Y, Yu C. Determination of glycemic monitor‑
ing marker 1,5‑anhydroglucitol in plasma by liquid chromatography‑
electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol 
Biomed Life Sci. 2008;875:459–64. doi:10.1016/j.jchromb.2008.09.033.
 28. Yabuuchi M, Masuda M, Katoh K, Nakamura T, Akanuma H. Simple 
enzymatic method for determining 1,5‑anhydro‑d‑glucitol in plasma for 
diagnosis of diabetes mellitus. Clin Chem. 1989;35:2039–43. http://www.
ncbi.nlm.nih.gov/pubmed/2791271 Accessed 14 June 2015.
 29. Danneel HJ, Rössner E, Zeeck A, Giffhorn F. Purification and charac‑
terization of a pyranose oxidase from the basidiomycete Peniophora 
gigantea and chemical analyses of its reaction products. Eur J Biochem. 
1993;214:795–802. http://www.ncbi.nlm.nih.gov/pubmed/8319689 
Accessed 10 Aug 2015.
